A complete application in a minute
Tailored resume and cover letter, ready to send.
Regeneron Pharmaceuticals, Inc. (USA) is seeking a Staff Accountant to join our Finance team. The role focuses on product revenue and SG&A accounting, collaborating with colleagues to ensure accurate month-end close and financial reporting.
You will prepare journal entries, run reconciliations, support SOX controls, and participate in ERP implementation efforts. Strong Excel skills and attention to detail are essential to help Regeneron maintain robust internal controls and drive continuous
We are looking for a Staff Accountant who is a collaborative team member, communicates effectively with colleagues, thrives in a dynamic environment, and is eager to take on challenges and contribute to Regeneron's growth. This position focuses on accounting duties within the Product Revenue and SG&A expense areas.
Salary Range (annually) $71,800.00 - $116,800.00
Benefits in the U.S. may include health and wellness programs (medical, dental, vision, life and disability insurance), fitness centers, 401(k) company match, family support benefits, equity awards, annual bonuses, paid time off, and paid leaves (e.g., military and parental leave) for eligible employees at all levels.
Regeneron is an equal‑opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion or belief (or lack thereof), sex, nationality, national or ethnic origin, civil status, age, citizenship status, membership of the Traveler community, sexual orientation, disability, genetic information, familial status, marital or registered civil partnership status, pregnancy or parental status, gender identity, gender reassignment, military or veteran status, or any other protected characteristic in accordance with applicable laws and regulations.
The Company will also provide reasonable accommodation to the known disabilities or chronic illnesses of an otherwise qualified applicant for employment, unless the accommodation would impose undue hardship on the operation of the Company’s business.